IL117151A - Antigen-H pylori having a molecular weight between 65-55 kDa or its segments, for the detection and diagnosis of H-pylori - Google Patents
Antigen-H pylori having a molecular weight between 65-55 kDa or its segments, for the detection and diagnosis of H-pyloriInfo
- Publication number
- IL117151A IL117151A IL11715196A IL11715196A IL117151A IL 117151 A IL117151 A IL 117151A IL 11715196 A IL11715196 A IL 11715196A IL 11715196 A IL11715196 A IL 11715196A IL 117151 A IL117151 A IL 117151A
- Authority
- IL
- Israel
- Prior art keywords
- protein
- pylori
- composition
- antigenic fragment
- antigen
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title claims abstract description 33
- 102000036639 antigens Human genes 0.000 title claims abstract description 33
- 108091007433 antigens Proteins 0.000 title claims abstract description 33
- 239000012634 fragment Substances 0.000 title claims description 28
- 238000001514 detection method Methods 0.000 title claims description 10
- 238000003745 diagnosis Methods 0.000 title claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 43
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 43
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 3
- 230000000890 antigenic effect Effects 0.000 claims description 34
- 239000000203 mixture Substances 0.000 claims description 28
- 108010046334 Urease Proteins 0.000 claims description 11
- 238000000034 method Methods 0.000 claims description 11
- 229960005486 vaccine Drugs 0.000 claims description 9
- 239000002671 adjuvant Substances 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 6
- 210000003296 saliva Anatomy 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 5
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 3
- 238000005119 centrifugation Methods 0.000 claims description 3
- 238000010828 elution Methods 0.000 claims description 3
- 238000005227 gel permeation chromatography Methods 0.000 claims description 3
- 230000002163 immunogen Effects 0.000 claims description 3
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 239000008188 pellet Substances 0.000 claims description 3
- 239000006228 supernatant Substances 0.000 claims description 3
- 238000003306 harvesting Methods 0.000 claims description 2
- 238000011176 pooling Methods 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 208000015181 infectious disease Diseases 0.000 description 11
- 238000012360 testing method Methods 0.000 description 10
- 230000028327 secretion Effects 0.000 description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000005875 antibody response Effects 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 150000001413 amino acids Chemical group 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 239000012153 distilled water Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 241000590002 Helicobacter pylori Species 0.000 description 3
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229940037467 helicobacter pylori Drugs 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 3
- 229960004906 thiomersal Drugs 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- 229920001817 Agar Polymers 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000007979 citrate buffer Substances 0.000 description 2
- 239000012470 diluted sample Substances 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 239000012614 Q-Sepharose Substances 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- 101710123661 Venom allergen 5 Proteins 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- FJWGYAHXMCUOOM-QHOUIDNNSA-N [(2s,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6s)-4,5-dinitrooxy-2-(nitrooxymethyl)-6-[(2r,3r,4s,5r,6s)-4,5,6-trinitrooxy-2-(nitrooxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-3,5-dinitrooxy-6-(nitrooxymethyl)oxan-4-yl] nitrate Chemical compound O([C@@H]1O[C@@H]([C@H]([C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O)O[C@H]1[C@@H]([C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@@H](CO[N+]([O-])=O)O1)O[N+]([O-])=O)CO[N+](=O)[O-])[C@@H]1[C@@H](CO[N+]([O-])=O)O[C@@H](O[N+]([O-])=O)[C@H](O[N+]([O-])=O)[C@H]1O[N+]([O-])=O FJWGYAHXMCUOOM-QHOUIDNNSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000012149 elution buffer Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 102000034238 globular proteins Human genes 0.000 description 1
- 108091005896 globular proteins Proteins 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000009629 microbiological culture Methods 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229940079938 nitrocellulose Drugs 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000012609 strong anion exchange resin Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/205—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Campylobacter (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K2039/106—Vibrio; Campylobacter; Not used, see subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cell Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9502899.9A GB9502899D0 (en) | 1995-02-15 | 1995-02-15 | Novel antigen |
Publications (2)
Publication Number | Publication Date |
---|---|
IL117151A0 IL117151A0 (en) | 1996-06-18 |
IL117151A true IL117151A (en) | 2001-06-14 |
Family
ID=10769595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL11715196A IL117151A (en) | 1995-02-15 | 1996-02-15 | Antigen-H pylori having a molecular weight between 65-55 kDa or its segments, for the detection and diagnosis of H-pylori |
Country Status (17)
Country | Link |
---|---|
EP (1) | EP0809653B1 (pt) |
JP (1) | JPH11503999A (pt) |
KR (1) | KR19980701698A (pt) |
CN (1) | CN1175955A (pt) |
AT (1) | ATE206138T1 (pt) |
AU (1) | AU714222B2 (pt) |
CA (1) | CA2212952A1 (pt) |
DE (1) | DE69615537T2 (pt) |
DK (1) | DK0809653T3 (pt) |
ES (1) | ES2164231T3 (pt) |
FI (1) | FI973335A0 (pt) |
GB (1) | GB9502899D0 (pt) |
IL (1) | IL117151A (pt) |
NO (1) | NO973753L (pt) |
NZ (1) | NZ301334A (pt) |
PT (1) | PT809653E (pt) |
WO (1) | WO1996025430A1 (pt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6599509B2 (en) * | 1997-09-02 | 2003-07-29 | Massachusetts Institute Of Technology | Compositions and methods comprising helicobacter antigens for treatment and prevention of inflammatory bowel disease |
CN1105185C (zh) * | 1998-11-30 | 2003-04-09 | 上海晶莹生物技术有限公司 | 基因表达幽门螺杆菌细胞毒素相关基因a蛋白抗原制备工艺 |
AUPQ854100A0 (en) * | 2000-07-03 | 2000-07-27 | Helirad Pty Ltd | Methods for monitoring treatment of helicobacter infection |
SE0101030D0 (sv) * | 2001-03-23 | 2001-03-23 | Nordic Bio Ab | Immunogenic cell surface proteins of helicobacter pylori |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5459041A (en) * | 1988-02-18 | 1995-10-17 | Enteric Research Laboratories, Inc. | Campylobacter pylori antigens and uses thereof for detection of Campylobacter pylori infection |
DE4139840B4 (de) * | 1990-12-04 | 2005-06-02 | Quidel Corp., San Diego | Antigen-Zubereitung zum Nachweis von H. pylori |
ES2119900T3 (es) * | 1992-04-29 | 1998-10-16 | Auspharm Int Ltd | Ensayo in vitro para helicobacter pylori. |
-
1995
- 1995-02-15 GB GBGB9502899.9A patent/GB9502899D0/en active Pending
-
1996
- 1996-02-15 KR KR1019970705094A patent/KR19980701698A/ko not_active Application Discontinuation
- 1996-02-15 CA CA002212952A patent/CA2212952A1/en not_active Abandoned
- 1996-02-15 WO PCT/GB1996/000351 patent/WO1996025430A1/en not_active Application Discontinuation
- 1996-02-15 AT AT96902390T patent/ATE206138T1/de not_active IP Right Cessation
- 1996-02-15 DE DE69615537T patent/DE69615537T2/de not_active Expired - Fee Related
- 1996-02-15 EP EP96902390A patent/EP0809653B1/en not_active Expired - Lifetime
- 1996-02-15 ES ES96902390T patent/ES2164231T3/es not_active Expired - Lifetime
- 1996-02-15 AU AU46728/96A patent/AU714222B2/en not_active Ceased
- 1996-02-15 NZ NZ301334A patent/NZ301334A/xx unknown
- 1996-02-15 DK DK96902390T patent/DK0809653T3/da active
- 1996-02-15 PT PT96902390T patent/PT809653E/pt unknown
- 1996-02-15 CN CN96191969A patent/CN1175955A/zh active Pending
- 1996-02-15 IL IL11715196A patent/IL117151A/en not_active IP Right Cessation
- 1996-02-15 JP JP8524773A patent/JPH11503999A/ja active Pending
-
1997
- 1997-08-14 NO NO973753A patent/NO973753L/no not_active Application Discontinuation
- 1997-08-14 FI FI973335A patent/FI973335A0/fi unknown
Also Published As
Publication number | Publication date |
---|---|
IL117151A0 (en) | 1996-06-18 |
FI973335A (fi) | 1997-08-14 |
NO973753D0 (no) | 1997-08-14 |
AU714222B2 (en) | 1999-12-23 |
DE69615537D1 (en) | 2001-10-31 |
EP0809653A1 (en) | 1997-12-03 |
EP0809653B1 (en) | 2001-09-26 |
NO973753L (no) | 1997-08-14 |
FI973335A0 (fi) | 1997-08-14 |
JPH11503999A (ja) | 1999-04-06 |
CN1175955A (zh) | 1998-03-11 |
DK0809653T3 (da) | 2001-11-19 |
ATE206138T1 (de) | 2001-10-15 |
WO1996025430A1 (en) | 1996-08-22 |
DE69615537T2 (de) | 2002-04-18 |
NZ301334A (en) | 1999-08-30 |
KR19980701698A (ko) | 1998-06-25 |
ES2164231T3 (es) | 2002-02-16 |
GB9502899D0 (en) | 1995-04-05 |
CA2212952A1 (en) | 1996-08-22 |
AU4672896A (en) | 1996-09-04 |
PT809653E (pt) | 2002-03-28 |
MX9706267A (es) | 1997-11-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FI112366B (fi) | Menetelmä organismin Borrelia burgdorferi OspA -polypeptidin ja sitä tuottavan organismin valmistamiseksi ja menetelmässä käytettäviä välineitä | |
US7022328B1 (en) | Therapeutic and diagnostic compositions | |
US6468545B1 (en) | Treatment and prevention of helicobacter infection | |
ZA200007255B (en) | Vaccine. | |
US5474905A (en) | Antibodies specific for streptococcus pneumoniae hemin/hemoglobin-binding antigens | |
JPH11504633A (ja) | 多量体の組換えウレアーゼワクチン | |
US20150293118A1 (en) | Cross-reactive determinants and methods for their identification | |
AU714222B2 (en) | Helicobacter pylori antigen | |
CA2233570C (en) | Detection, prevention and treatment of papillomatous digital dermatitis | |
WO2000069905A1 (en) | LAWSONIA DERIVED GENE AND RELATED OmpH POLYPEPTIDES, PEPTIDES AND PROTEINS AND THEIR USES | |
Hirschl | Frequency of occurrence of Campylobacter pylori and analysis of the systemic and local immune response | |
US7052697B1 (en) | Lawsonia derived gene and related OmpH polypeptides, peptides and proteins and their uses | |
WO1998032768A1 (en) | H. pylori antigens | |
MXPA97006267A (en) | Antigen of helicobacter pyl | |
JP2009029825A (ja) | 抗原 | |
US20020071850A1 (en) | Helicobacter pylori antigen | |
IE891022L (en) | Diagnosis of mycobacterium bovis infection | |
CN110859954B (zh) | 一种包含B群脑膜炎球菌fHBP抗原的组合物及其制备方法与应用 | |
JP3335622B2 (ja) | 細菌からトランスフェリン及びラクトフェリン受容体タンパク質を分離及び精製する方法並びにこれらを含有するワクチンを調製する方法 | |
EP0710119A1 (en) | $i(PASTEURELLA HAEMOLYTICA) SUBUNIT VACCINE CONTAINING CAPSULAR POLYSACCHARIDE AND MURAMYL DIPEPTIDE | |
WO2002028351A9 (en) | Recombinant mucin binding proteins from steptococcus pneumoniae | |
Reitan et al. | Further characterization including preliminary chemical analysis of antigen MLW1 from Mycobacterium leprae | |
WO2000046242A2 (en) | 19 KILODALTON PROTEIN OF $i(HELICOBACTER PYLORI) | |
RU97115365A (ru) | Антиген helicobacter pylori | |
EP1131347A2 (en) | Product |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FF | Patent granted | ||
MM9K | Patent not in force due to non-payment of renewal fees |